Obstructive Sleep Apnea News and Research

RSS

Obstructive sleep apnea (OSA) is a major heath problem. In the United States, at least 17 million people have moderate to severe OSA, which is characterized by heavy snoring, airway blockage and frequent awakenings during sleep.

Special issue of NeuroRehabilitation journal devoted to HI-BI published

IOS Press announces publication of a special issue of NeuroRehabilitation: An International Journal devoted specifically to hypoxic-ischemic brain injury (HI-BI), a significant disruption of brain function due to a deficient supply of oxygen to the brain.

24 Feb 2010

Study shows severe OSA suppresses cognitive experience of nightmare recall

A study in the Feb. 15 issue of the Journal of Clinical Sleep Medicine shows that patients with severe obstructive sleep apnea (OSA) report a significantly lower frequency of nightmares than patients with mild or no sleep apnea, indicating that OSA suppresses the cognitive experience of nightmare recall.

15 Feb 2010

Bioethicists create easy-to-remember checklist to assess patient's decision-making capacity in emergency

Physicians in training and bioethicists at Johns Hopkins have created an easy-to-remember checklist to help medical students and clinicians quickly assess a patient's decision-making capacity in an emergency.

5 Feb 2010

Study could lead to non-surgical alternatives for tonsillectomies

Children with obstructive sleep apnea (OSA) may one day be able to have an injection or use a throat spray instead of getting their tonsils removed to cure their snoring, according to a new study from the University of Chicago, which found that a specific gene product may be responsible for the proliferation of adenotonsillar tissue that can cause pediatric OSA.

4 Feb 2010

Study assesses gray matter concentration deficits in multiple brain areas of people with OSA

A study in the Feb. 1 issue of the journal SLEEP found gray matter concentration deficits in multiple brain areas of people with severe obstructive sleep apnea (OSA). The study suggests that the memory impairment, cardiovascular disturbances, executive dysfunctions, and dysregulation of autonomic and respiratory control frequently observed in OSA patients may be related to morphological changes in brain structure.

1 Feb 2010

NovaSom Diagnostic System approved for diagnostic evaluation of adults with OSA

Some 18-20 million Americans are at risk for Obstructive Sleep Apnea (OSA) and of those, only 5 to 10 percent have been diagnosed. Studies prove that fatality is a major risk of undiagnosed and untreated OSA; however, once detected, OSA can be readily and successfully treated.

29 Jan 2010

ASA urges patients to make lifestyle changes before opting for complicated surgeries

At a time of year when people make plans to drop a few pounds, perhaps even consider bariatric surgery, the American Society of Anesthesiologists (ASA) wants to ensure the public has the facts regarding one's weight and the impact it may have on his or her anesthesia experience.

18 Jan 2010

OSA adversely affects glucose control in patients with type 2 diabetes

Obstructive Sleep Apnea (OSA) adversely affects glucose control in patients with type 2 diabetes, according to a study conducted by researchers at the University of Chicago.

18 Jan 2010

Mylan sued in connection with the filing of ANDA with FDA for Armodafinil Tablets

Mylan Inc. (Nasdaq: MYL) today confirmed that it was sued by Cephalon Inc. and Cephalon France in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Armodafinil Tablets, 50 mg, 150 mg and 250 mg.

12 Jan 2010

Positive results from phase 2 study evaluating the safety and efficacy of Qnexa announced

VIVUS, Inc. today announced positive results from a phase 2 study evaluating the safety and efficacy of Qnexa®, an investigational drug, for the treatment of obstructive sleep apnea (OSA). VIVUS recently completed phase 3 development of Qnexa for the treatment of obesity and submitted a New Drug Application (NDA) to the FDA for that indication.

7 Jan 2010

Watson Laboratories files ANDA to seek FDA's approval to market Nuvigil

Watson Pharmaceuticals, Inc., a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc., a Nevada Corporation, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its 50 mg, 100 mg, 150mg, 200 mg, and 250mg strength armodafinil tablets prior to the expiration of patents owned by Cephalon France.

7 Jan 2010

Erectile dysfunction linked to RLS in older men

A study in the Jan. 1 issue of the journal Sleep shows that erectile dysfunction was more common in older men with restless leg syndrome (RLS) than in those without RLS, and the magnitude of this association increased with a higher frequency of RLS symptoms.

3 Jan 2010

FDA extends action date for its review of Cephalon's sNDA for NUVIGIL Tablets

Cephalon, Inc. today announced that the U.S. Food and Drug Administration (FDA) has extended the action date to March 29, 2010, for its review of the supplemental New Drug Application (sNDA) for NUVIGIL® (armodafinil) Tablets [C-IV].

22 Dec 2009

InHealth to further understand socioeconomic impact of medical devices and diagnostics

As the Institute for Health Technology Studies (InHealth) marks its five-year milestone, the research and educational nonprofit is taking stock of its contributions to objective evidence about the roles that medical technologies play in the economy, in the healthcare system, and in patients' lives.

19 Dec 2009

Ethicon and Acclarent announce definitive merger agreement

Ethicon, Inc., a Johnson & Johnson company and a worldwide leader in surgical care, and Acclarent, Inc., a privately held medical technology company dedicated to designing, developing and commercializing devices that address conditions affecting the ear, nose and throat (ENT), today announced a definitive merger agreement whereby Ethicon will acquire Acclarent in an all-cash transaction for approximately $785 million net of estimated cash on hand at time of closing.

17 Dec 2009

Being obese increases the risk for developing OSA in adolescents, study shows

A study in the Dec. 15 issue of the Journal of Clinical Sleep Medicine shows that being overweight or obese increases the risk for developing obstructive sleep apnea (OSA) in adolescents but not in younger children.

15 Dec 2009

New technique to determine pediatric OSA

Researchers at the University of Chicago have discovered a technique that is able to determine whether a child has obstructive sleep apnea (OSA) or habitual snoring by screening their urine.

7 Dec 2009

ImThera Medical implants its aura6000 neurostimulation device in two OSA patients

ImThera Medical, Inc. today announced that two patients have been surgically implanted with ImThera’s aura6000™ neurostimulation device for treating tongue-based Obstructive Sleep Apnea (OSA). Patients are being enrolled in ImThera’s pilot clinical investigation in Belgium with the first results expected to be published in the first half of 2010.

2 Dec 2009

Sleep apnea is associated with cardiovascular risk factors among kidney transplant patients

Sleep apnea is common in individuals who receive a kidney transplant and is associated with increased risk of high blood pressure, heart disease or stroke, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN).

20 Nov 2009

CMS policy changes to drive the sleep management devices market

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, policy changes made by the Center for Medicare and Medicaid Services (CMS) will cause a surge in obstructive sleep apnea (OSA) diagnostic testing and treatment. MRG's new US Market Opportunities for Respiratory and Sleep Management Devices 2010 report finds that increasing reimbursement opportunities for OSA diagnosis and treatment will drive the OSA market to $1.5 billion by 2014.

17 Nov 2009